Navigation Links
Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
Date:5/31/2011

EAST HANOVER, N.J., June 1, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") will showcase data from 140 abstracts on its current oncology products and investigational agents at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). These data underscore the company's commitment to developing treatments to improve the lives of patients with cancer.

"Through our commitment to R&D and collaborations with the scientific and patient communities, we continue to bring targeted treatments to patients living with cancer and other diseases for which there is an unmet need," said Hervé Hoppenot, President, Novartis Oncology. "Our broad and deep portfolio of development programs gives us multiple opportunities to further advance treatments for the millions of patients and their families affected by these diseases."

Highlighted at the ASCO meeting, taking place from June 3 - 7 in Chicago, will be results from key Phase III studies on Novartis products and compounds, including a trial on adjuvant treatment with Gleevec® (imatinib mesylate) tablets* in patients following resection of KIT (CD117)-positive gastrointestinal stromal tumors (GIST) featured at the plenary session on June 5, and two pivotal studies of the Janus kinase (JAK) inhibitor, INC424 (ruxolitinib), in patients with myelofibrosis on June 6(1). In addition, a study of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), showing patients on Tasigna® (nilotinib) 150 mg capsules are less likely to develop mutations than those taking Gleevec, will be presented on June 6(1).

Also featured at the Annual Congress will be results from two sub-analyses of the landmark Medical Research Council Myeloma IX clinical trial comparing the effect of Zometa® (zoledronic acid) Injection versus clodronate, on overall survival, progression-free survival and skeletal-related events when used with
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 Nektar Therapeutics (Nasdaq: NKTR ) ... June 30, 2014. Cash and investments in ... compared to $309.1 million at March 31, 2014."The second half ... we look forward to significant milestones for a number of ... Chief Executive Officer of Nektar. "The first of these is ...
(Date:7/31/2014)... July 31, 2014  Decision Resources Group,s ... about by the Affordable Care Act (ACA), ... of pharmaceutical therapies. The ACA altered how ... new regulations and expanded access via government-supported ... health exchanges—state-based marketplaces set up by states ...
(Date:7/31/2014)... July 31, 2014 Hovione today announced ... has successfully passed a pre-approval inspection by the US ... out by the FDA Consumer Safety Officer, Ms. Britanny ... 21 st July and concluded on the 25 th ... the principles and guidelines of Good Manufacturing Practices (GMP) and ...
Breaking Medicine Technology:Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2
... challenges of treating acne in a clinical setting are ... program that provides physicians with a viable alternative to ... to bridge the gap between science and skin health ... Light device. The TRIA |MD referral program ...
... WORCESTER, Mass. and TORONTO, Aug. 2, 2011 Generex ... to provide its shareholders with a corporate update of ... Mark Fletcher as President & Chief Executive Officer on ... President & Chief Executive Officer of Generex, I have ...
Cached Medicine Technology:TRIA Beauty Leading the Charge in Bridging Gap Between Science and Skin Health 2TRIA Beauty Leading the Charge in Bridging Gap Between Science and Skin Health 3Generex Provides Corporate Update 2Generex Provides Corporate Update 3Generex Provides Corporate Update 4Generex Provides Corporate Update 5Generex Provides Corporate Update 6Generex Provides Corporate Update 7Generex Provides Corporate Update 8
(Date:7/31/2014)... A program for anyone looking to experience weight ... of Colorado Anschutz Health and Wellness Center (AHWC) ... transformation program. , “Extreme Weight Loss: Destination Boot ... an evidenced-based program inspired by the unscripted series “Extreme ... season, the show has participants spending their first three ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 Dr. ... closure in front of an enthusiastic audience of international ... Trichophytic Closure improves the appearance of a patient’s ... results of this procedure are minimally detectable in most ... technique improves on the original method of donor wound ...
(Date:7/31/2014)... You’re having a wonderful summer—sunning, gardening, enjoying BBQs ... chills and fever, headache, stiff neck, achey joints, and a ... it could actually be the first sign of Lyme ... is greater than you might think. Until last year, it ... U.S. annually. But the Centers for Disease Control and Prevention ...
(Date:7/31/2014)... San Diego, CA (PRWEB) July 31, 2014 ... by the Philadelphia Business Journal , Endo International, one ... agreed to settle thousands of transvaginal claims for $830 ... Systems Products Liability Litigation (MDL No. 2325). Melinda Helbock, ... A.P.C., said she agrees with the settlement and is ...
(Date:7/31/2014)... LDM Global ( http://www.ldmglobal.com ) announces ... is simplified and predictable with fixed fees across the ... leading international provider of legal discovery management services for ... glaringly apparent that both the courts and legal counsel ... the complex pricing structure that plagues the litigation support ...
Breaking Medicine News(10 mins):Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 2Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 3Health News:Novel Technique in Wound Closure Delivers More Discreet Results in Hair Transplant Patients 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 3Health News:San Diego Product Liability Firm Provides Commentary on the Latest Developments in Transvaginal Mesh Litigation 2Health News:LDM Global Announces Predictable Simple Fixed-Fee Pricing 2
... Phoebe Prince was stalked ... staple of youth culture. Keith Deltano is using comedy to fight this serious problem., ... (PRWEB) May 24, 2010 -- Phoebe Prince ... where students are being bullied to death, is comedy the appropriate vehicle to use to address ...
... ... Food & Drug Administration’s Center for Drug Evaluation and Research (CDER) will soon ... including “SPF,” “anti-aging,” or “anti-wrinkle,” according to Benjamin L. England, former 17-year FDA ... ...
... Company ... ... Corporation announced it has joined the American Academy of Healthcare Interior Designers (AAHID) as ... the knowledge, skills and abilities of healthcare interior designers. Board Certified Healthcare Interior Design ...
... ... been named by the United States Public Health Service Commissioned Officers Association as the 2010 ... individuals who have provided significant leadership to the advancement of the health of the American ... ...
... ... Breaks , ... -- A lawsuit has been filed in the Federal District Court of the United States for ... of current and former CVS employees alleging violations of the Fair Labor Standards Act and New ...
... ... 501(c)(3) application is filed, it has a bank account, and it even has a ... What it needs now is a logo, and it has launched a nationwide contest ... Spice House, singer Gretchen Wilson, and writer Michael Z. Williamson. , ...
Cached Medicine News:Health News:Bullying Assembly Uses Comedy to Reach Students 2Health News:Bullying Assembly Uses Comedy to Reach Students 3Health News:FDA to Take Up Major Enforcement Action Against Cosmetics Manufacturers With Illegal “Anti-Aging” Labeling Claims, According to FDAImports.com, LLC 2Health News:FDA to Take Up Major Enforcement Action Against Cosmetics Manufacturers With Illegal “Anti-Aging” Labeling Claims, According to FDAImports.com, LLC 3Health News:FDA to Take Up Major Enforcement Action Against Cosmetics Manufacturers With Illegal “Anti-Aging” Labeling Claims, According to FDAImports.com, LLC 4Health News:InPro Becomes AAHID Industry Partner 2Health News:Health Leader of the Year for 2010 - U.S. Senator Daniel K. Inouye 2Health News:Health Leader of the Year for 2010 - U.S. Senator Daniel K. Inouye 3Health News:Health Leader of the Year for 2010 - U.S. Senator Daniel K. Inouye 4Health News:National Employee Collective and Class Action Lawsuit Filed Against CVS 2Health News:Art Contest for New Charity With A History 2Health News:Art Contest for New Charity With A History 3Health News:Art Contest for New Charity With A History 4
1200 L, Racked, 96 tips/rack, 10 racks/box Recommended for 1200 L SofTouch electronic pipettes....
The larger volume alternative to the ART Gel 20P, this gel loading tip can load up to 100 L....
... West Nile Virus IgM Capture,DxSelect is ... West Nile virus in human serum. ... Nile Virus IgG DxSelect,the test is ... of,meningioencephalitis, as an aid in the ...
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
Medicine Products: